Human medicines European public assessment report (EPAR): Avzivi, bevacizumab, Date of authorisation: 26/07/2024, Revision: 2, Status: Authorised

Procedural advice for vaccine platform technology master file (vPTMF) certification

Procedural advice for veterinary vaccine antigen master file (VAMF) certification

HMPC meeting report on European Union herbal monographs, guidelines and other activities - 19-21 January 2026

European Medicines Agency’s data protection notice for EudraVigilance Human (EV)

Start of procedure: Extension of marketing authorisation (12 December 2025 - 29 January 2026)

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (12 December 2025 - 29 January 2026)

Industry stakeholder webinar on revised environmental risk assessment guideline for medicinal products for human use - 1 year experience, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 October 2025, 14:30 (CEST) to 6 October 2025, 17:00 (CEST)

Human medicines European public assessment report (EPAR): Sugammadex Amomed, sugammadex, Date of authorisation: 10/01/2023, Revision: 5, Status: Authorised

Epidemiological data on blood transmissible infections - Scientific guideline